Paolino Marco, Saletti Mario, Venditti Jacopo, Zacchei Arianna, Donati Alessandro, Bonechi Claudia, Giuliani Germano, Lamponi Stefania, Cappelli Andrea
Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, Via Aldo Moro 2, 53100 Siena, Italy.
Pharmaceuticals (Basel). 2025 Mar 27;18(4):473. doi: 10.3390/ph18040473.
: Crown ethers have received increasing interest owing to their ability to form stable complexes with cations. This molecular feature has been successfully exploited in the development of biologically relevant ionophores. : In order to obtain innovative crown ethers derivatives, a Morita-Baylis-Hillman adduct (MBHA) acetate () bearing a phenylacetylene moiety was dimerized via the click-chemistry CuAAC reaction with oligo(ethylene glycol) diazide derivatives to build-up a small series of dimeric MBHA derivatives (). These dimeric MBHA derivatives were reacted with n-butylamine to afford tunable macrocyclic crown ether-paracyclophane hybrid architectures (). : Compounds (,)-, (,)-, showed, in human breast cancer MDA-MB-231 and human melanoma A375 cells, IC values comparable with those of reference anticancer agent Doxorubicin. : This exploration approach provides original new macrocyclic architectures potentially useful as anticancer agents.
冠醚因其与阳离子形成稳定配合物的能力而受到越来越多的关注。这种分子特性已在生物相关离子载体的开发中得到成功应用。为了获得创新的冠醚衍生物,将带有苯乙炔部分的乙酸Morita-Baylis-Hillman加合物(MBHA)()通过点击化学CuAAC反应与低聚乙二醇二叠氮化物衍生物二聚,以构建一小系列二聚体MBHA衍生物()。这些二聚体MBHA衍生物与正丁胺反应,得到可调节的大环冠醚-对环芳烷杂化结构()。化合物(,)-、(,)-在人乳腺癌MDA-MB-231细胞和人黑色素瘤A375细胞中显示出与参考抗癌药物阿霉素相当的IC值。这种探索方法提供了可能用作抗癌剂的新颖的新大环结构。